NeuroPace announces publication of 3-year results from RNS System PAS

NeuroPace (NPCE) announced a major milestone in its clinical evidence program with the publication of 3-year results from the RNS System Post-Approval Study, PAS, in Neurology, alongside the Company’s recent presentation of 12- and 18-month data from its ongoing NAUTILUS trial at the 2026 American Academy of Neurology Annual Meeting. The published PAS results reinforce the RNS System’s well-established value in drug-resistant focal epilepsy, while the NAUTILUS presentation highlights continued progress in expanding the reach of responsive neurostimulation into idiopathic generalized epilepsy. In addition, NeuroPace recently presented 12- and 18-month data from its ongoing NAUTILUS study evaluating the RNS System as an adjunctive therapy for the treatment of antiseizure medication-resistant idiopathic generalized epilepsy with generalized tonic-clonic seizures. 18-month results showed a 77% median reduction in GTC seizures compared with baseline, with rapid and sustained reductions over time.